Abstract：Insulin detemir is a new basal insulin analogue, which could form the dual hexamer-albumin complex in the blood to have a prolonged hypoglycemic effect. Its clinical efficacy is quite satisfactory, with low incidence of hypoglycemia, low within-subject variability in blood glucose concentration, less weight gain and other clinical features, and less weight gain is the unique advantage. A number of trials have shown that BOT (“basal+oral”therapy) with once-daily detemir achieved effective control of blood glucose. To adjust the dose of insulin, there is no significant difference between 303 algorithm and doctor’s guidance.
2013, Vol. 11 
